Good Growth Opportunities in Global Lung Cancer Diagnostics Market

Pune, Maharashtra -- (SBWire) -- 02/15/2019 --Fact.MR, in its recent report, estimates the global lung cancer diagnostics market to register an impressive 7.3% CAGR during the forecast period 2017 to 2022.

The growth of the global market for lung cancer diagnostics is primarily attributed to increasing developments in lung cancer-specific biomarkers. These diagnostic tools are expected to facilitate personalized treatment approach towards lung malignancies. A number of biomarkers exist in the research pipeline. In the recent past, Epigenomics AG launched a new test based on blood utilizing DNA methylation biomarkers, whose developments are in the process. The initial results obtained from these tests have promised early diagnosis of lung cancer. Such incidences are expected to increase demand for lung cancer diagnostics across the globe.

Competition Tracking

Novel product launches for lung cancer diagnostics is a key strategy adopted by leading players in the global market, in order to increase their product portfolio. Fact.MR's report profiles key market players, which include Illumina, Inc., Abbott Laboratories, Thermo Fischer Scientific, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString Technologies, Inc., Myriad Genetics, Inc., Roche Holding AG, and Danaher Corporation.

Request Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=49

Increasing Awareness Programs for Lung Cancer to Drive Growth of the Market

A number of awareness programs associated with lung cancer and its related symptoms have been initiated in order to enhance the diagnosis and screening rates of individuals with high risks of developing lung malignancies. For example – In the United Kingdom, November is considered to be the lung cancer awareness month, and is supported by Roy Castle Lung Cancer Foundation. Such initiatives help in raising awareness about early detection and diagnosis of lung cancer.

CA tests will continue to be the most lucrative tests for lung cancer diagnostics in the market. Revenue from CA tests will account for US$ 889.3 Mn by 2022-end. Angiogenesis inhibitor is expected to witness the fastest expansion among test type in the market, followed by HER 2 tests. Revenue from ALK tests for lung cancer diagnostics will continue to remain low in the market.

Request/View Toc@ https://www.factmr.com/connectus/sample?flag=T&rep_id=49

Hospital-associated Labs to Remain the Most Lucrative End-Users of Lung Cancer Diagnostics

Hospital-associated labs will remain the most lucrative end-users of lung cancer diagnostics in the global market, with revenues estimated to reach nearly US$ 1,500 Mn by 2022-end. Cancer research institutes will continue to exhibit the fastest expansion in the global lung cancer diagnostics market, followed by independent diagnostic laboratories. In addition, independent diagnostic laboratories are expected to be the second largest end-users of lung cancer diagnostics throughout the forecast period.

On the basis of indication, although non-small cell lung cancer is expected to remain sought-after in the market, small cell-lung cancer is expected to exhibit the fastest expansion through 2022. Revenue from non-small cell lung cancer is expected to remain largest during the forecast period. In contrast, revenue from small cell lung cancer will continue to be low in the global lung cancer diagnostics market.

Speak To Research Analyst for Detailed Insights @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=49

Table of COntents Covered in the report are:

Chapter 1. Global Lung Cancer Diagnostics Market - Executive Summary. 12

Chapter 2. Global Lung Cancer Diagnostics Market Overview. 14
2.1. Introduction. 14
2.1.1. Global Lung Cancer Diagnostics Market Taxonomy. 14
2.1.2. Global Lung Cancer Diagnostics Market Definition. 14
2.2. Global Lung Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 15
2.2.1. Global Lung Cancer Diagnostics Market Y-o-Y Growth. 15
2.3. Global Lung Cancer Diagnostics Market Dynamics. 15
2.3.1. Drivers. 15
2.3.2. Restraints. 15
2.3.3. Trends. 16
2.4. Supply Chain. 16
2.5. Key Participants Market Presence (Intensity Map) By Region. 16

Access This Report @ https://www.factmr.com/checkout/49/S

Chapter 3. Global Lung Cancer Diagnostics Market Analysis and Forecast By Test Type. 17
3.1. Global Lung Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 17
3.1.1. CA Test Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 17
3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 17
3.1.1.2. Market Share Comparison, By Region. 19
3.1.1.3. Y-o-Y growth Comparison, By Region. 19
3.1.2. HER2 Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 20
3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 20
3.1.2.2. Market Share Comparison, By Region. 22
3.1.2.3. Y-o-Y growth Comparison, By Region. 22
3.1.3. ALK Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 23
3.1.3.1. Revenue (US$ Mn) Comparison, By Region. 23
3.1.3.2. Market Share Comparison, By Region. 25
3.1.3.3. Y-o-Y growth Comparison, By Region. 25
3.1.4. Angiogenesis Inhibitor Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 26
3.1.4.1. Revenue (US$ Mn) Comparison, By Region. 26
3.1.4.2. Market Share Comparison, By Region. 28
3.1.4.3. Y-o-Y growth Comparison, By Region. 28
3.1.5. EGFR Mutation Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 29
3.1.5.1. Revenue (US$ Mn) Comparison, By Region. 29
3.1.5.2. Market Share Comparison, By Region. 31
3.1.5.3. Y-o-Y growth Comparison, By Region. 31
3.1.6. KRAS Mutation Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 32
3.1.6.1. Revenue (US$ Mn) Comparison, By Region. 32
3.1.6.2. Market Share Comparison, By Region. 34
3.1.6.3. Y-o-Y growth Comparison, By Region. 34
3.1.7. Others Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 35
3.1.7.1. Revenue (US$ Mn) Comparison, By Region. 35
3.1.7.2. Market Share Comparison, By Region. 37
3.1.7.3. Y-o-Y growth Comparison, By Region. 37

Chapter 4. Global Lung Cancer Diagnostics Market Analysis and Forecast By End User. 39
4.1. Global Lung Cancer Diagnostics Market Size and Forecast By End User, 2012-2022. 39
4.1.1. Hospital Associated Labs Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 39
4.1.1.1. Revenue (US$ Mn) Comparison, By Region. 39
4.1.1.2. Market Share Comparison, By Region. 41
4.1.1.3. Y-o-Y growth Comparison, By Region. 41
4.1.2. Independent Diagnostic Laboratories Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 42
4.1.2.1. Revenue (US$ Mn) Comparison, By Region. 42
4.1.2.2. Market Share Comparison, By Region. 44
4.1.2.3. Y-o-Y growth Comparison, By Region. 44
4.1.3. Cancer Research Institutes Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 45
4.1.3.1. Revenue (US$ Mn) Comparison, By Region. 45
4.1.3.2. Market Share Comparison, By Region. 47
4.1.3.3. Y-o-Y growth Comparison, By Region. 47
4.1.4. Others Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 48
4.1.4.1. Revenue (US$ Mn) Comparison, By Region. 48
4.1.4.2. Market Share Comparison, By Region. 50
4.1.4.3. Y-o-Y growth Comparison, By Region. 50

Chapter 5. Global Lung Cancer Diagnostics Market Analysis and Forecast By Indication. 52
5.1. Global Lung Cancer Diagnostics Market Size and Forecast By Indication, 2012-2022. 52
5.1.1. Non Small-cell Lung Cancer Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 52
5.1.1.1. Revenue (US$ Mn) Comparison, By Region. 52
5.1.1.2. Market Share Comparison, By Region. 54
5.1.1.3. Y-o-Y growth Comparison, By Region. 54
5.1.2. Small-cell Lung Cancer Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 55
5.1.2.1. Revenue (US$ Mn) Comparison, By Region. 55
5.1.2.2. Market Share Comparison, By Region. 57
5.1.2.3. Y-o-Y growth Comparison, By Region. 57

Chapter 6. Global Lung Cancer Diagnostics Market Analysis and Forecast By Region. 59
6.1. Global Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 59
6.1.1. North America Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 59
6.1.1.1. Revenue (US$ Mn) Comparison, By Test Type. 59
6.1.1.2. Revenue (US$ Mn) Comparison, By End User. 61
6.1.1.3. Revenue (US$ Mn) Comparison, By Indication. 62
6.1.2. Latin America Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 64
6.1.2.1. Revenue (US$ Mn) Comparison, By Test Type. 64
6.1.2.2. Revenue (US$ Mn) Comparison, By Indication. 67
6.1.3. Europe Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 69
6.1.3.1. Revenue (US$ Mn) Comparison, By Test Type. 69
6.1.3.2. Revenue (US$ Mn) Comparison, By End User. 71
6.1.3.3. Revenue (US$ Mn) Comparison, By Indication. 72
6.1.4. Japan Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 74
6.1.4.1. Revenue (US$ Mn) Comparison, By Test Type. 74
6.1.4.2. Revenue (US$ Mn) Comparison, By Indication. 77
6.1.5. APEJ Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 79
6.1.5.1. Revenue (US$ Mn) Comparison, By Test Type. 79
6.1.5.2. Revenue (US$ Mn) Comparison, By End User. 81
6.1.5.3. Revenue (US$ Mn) Comparison, By Indication. 82
6.1.6. MEA Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 84
6.1.6.1. Revenue (US$ Mn) Comparison, By Test Type. 84
6.1.6.2. Revenue (US$ Mn) Comparison, By End User. 86
6.1.6.3. Revenue (US$ Mn) Comparison, By Indication. 87

Chapter 7. North America Lung Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 90
7.1. US Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 90
7.1.1. Revenue (US$ Mn) Comparison, By Test Type. 90
7.1.2. Revenue (US$ Mn) Comparison, By End User. 91
7.1.3. Revenue (US$ Mn) Comparison, By Indication. 91
7.2. Canada Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 92
7.2.1. Revenue (US$ Mn) Comparison, By Test Type. 92
7.2.2. Revenue (US$ Mn) Comparison, By End User. 93
7.2.3. Revenue (US$ Mn) Comparison, By Indication. 94

Chapter 8. Latin America Lung Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 96
8.1. Brazil Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 96
8.1.1. Revenue (US$ Mn) Comparison, By Test Type. 96
8.1.2. Revenue (US$ Mn) Comparison, By End User. 97
8.1.3. Revenue (US$ Mn) Comparison, By Indication. 97
8.2. Mexico Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 98
8.2.1. Revenue (US$ Mn) Comparison, By Test Type. 98
8.2.2. Revenue (US$ Mn) Comparison, By End User. 99
8.2.3. Revenue (US$ Mn) Comparison, By Indication. 100
8.3. Argentina Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 101
8.3.1. Revenue (US$ Mn) Comparison, By Test Type. 101
8.3.2. Revenue (US$ Mn) Comparison, By End User. 102
8.3.3. Revenue (US$ Mn) Comparison, By Indication. 103

And Continue...

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Rohit Bhisey
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com

Web: https://www.factmr.com/
Read Industry News at - https://theswisstimes.com